| Cystic Fibrosis |
| Not yet recruiting | 1 | 30 | | | Dr Conroy Wong, Health Research Council, New Zealand | non-cystic fibrosis bronchiectasis | | | | |
ACTRN12624000739516: A Phase 1 study to evaluate the safety and pharmacokinetics of single and multiple doses of SION-719 in healthy participants |
|
|
| Not yet recruiting | 1 | 96 | | | Sionna Therapeutics, Inc, Sionna Therapeutics, Inc | Cystic Fibrosis | | | | |
| Recruiting | 1 | 30 | | | Dr Adeline Lim, Professor Claire Wainwright | Cystic Fibrosis, Cystic Fibrosis Related Liver Disease | | | | |
NCT06238856: Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa |
|
|
| Completed | 1 | 18 | NA | SLIT™ Amikacin, TR02, Placebo | Insmed Incorporated | Cystic Fibrosis | 02/05 | 02/05 | | |
NCT03104855: Clearance of 25-hydroxyvitamin D in Cystic Fibrosis |
|
|
| Completed | 1 | 10 | US | d6-25-hydroxyvitamin D3 | University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Cystic Fibrosis | 10/18 | 09/23 | | |
ABBV-576 DDI, NCT05530278: A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis |
|
|
| Completed | 1 | 24 | US | Galicaftor, ABBV-576, Navocaftor, Midazolam | AbbVie | Healthy Volunteers | 11/22 | 11/22 | | |
NCT06217952: Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers |
|
|
| Completed | 1 | 32 | RoW | SPL84, Placebo | SpliSense Ltd. | Cystic Fibrosis | 08/23 | 08/23 | | |
NCT05437120: Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment |
|
|
| Completed | 1 | 16 | US | VX-121/TEZ/D-IVA, VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656, VX-121/tezacaftor/deutivacaftor | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 03/23 | 03/23 | | |
NCT04643587: Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) |
|
|
| Completed | 1 | 64 | Europe | CSL787, Placebo | CSL Behring | Noncystic Fibrosis Bronchiectasis (NCFB) | 03/23 | 03/23 | | |
NCT05867147: An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants |
|
|
| Completed | 1 | 56 | US | Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 06/23 | 06/23 | | |
| Recruiting | 1 | 40 | US | Gallium nitrate, Ga, GaN3O9, IV gallium, ganite | Chris Goss, Cystic Fibrosis Foundation | Nontuberculous Mycobacterium Infection | 09/24 | 06/25 | | |
| Recruiting | 1 | 149 | Europe, RoW | ARO-RAGE, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma | 12/24 | 02/25 | | |
| Recruiting | 1 | 159 | US | VX-828, Placebo, Itraconazole, Midazolam | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 04/25 | 04/25 | | |
NCT02748798: Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders |
|
|
| Recruiting | 1 | 160 | Canada | HP 3He, Hyperpolarized helium 3, HP 129Xe, Hyperpolarized xenon 129, PFP, Perfluoropropane, SF6, Sulfur hexafluoride, 129Xe Small and Large Human Lung Coil, 3He Human Lung Coil, PFP and SF6 Human Lung Coil | Thunder Bay Regional Health Research Institute, Thunder Bay Regional Health Sciences Centre, St. Joseph's Care Group, Lakehead University | Lung Transplant, Lung Resection, Lung Cancer, Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Emphysema, Mesothelioma, Asbestosis, Pulmonary Embolism, Interstitial Lung Disease, Pulmonary Fibrosis, Bronchiectasis, Seasonal Allergies, Cold Virus, Lung Infection, Pulmonary Hypertension, Pulmonary Dysplasia, Obstructive Sleep Apnea | 12/23 | 12/23 | | |
NCT04166396: Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis |
|
|
| Recruiting | 1 | 36 | US | Resveratrol, NR, Placebo | Virginia Commonwealth University | Cystic Fibrosis | 01/25 | 01/25 | | |
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003 |
|
|
| Recruiting | 1 | 60 | US | ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4. | Anagram Therapeutics, Inc. | Exocrine Pancreatic Insufficiency | 01/24 | 06/24 | | |
NCT06237335: A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants |
|
|
| Recruiting | 1 | 32 | RoW | RCT2100, Placebo | ReCode Therapeutics | Cystic Fibrosis | 05/24 | 08/24 | | |
NCT06299709: A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) |
|
|
| Completed | 1 | 34 | US | VNZ/TEZ/D-IVA, VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, Vanzacaftor/tezacaftor/deutivacaftor | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 05/24 | 05/24 | | |
NCT06299696: A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists |
|
|
| Completed | 1 | 10 | US | VNZ/TEZ/D-IVA, VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, Vanzacaftor/tezacaftor/deutivacaftor | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 04/24 | 04/24 | | |
NCT05712538: Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. |
|
|
| Recruiting | 1 | 38 | RoW | ARCT-032, Placebo | Arcturus Therapeutics, Inc., Novotech CRO | Cystic Fibrosis | 05/24 | 05/24 | | |
|
NCT03435939: Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240 |
|
|
| Recruiting | 1 | 16 | US | Losartan, Cozaar | University of Kansas Medical Center | Cystic Fibrosis | 07/24 | 07/24 | | |
NCT06312787: A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation |
|
|
| Completed | 1 | 15 | US | VX-118 | Vertex Pharmaceuticals Incorporated | Cystic Fibrosis | 05/24 | 05/24 | | |
NCT05095246: A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis |
|
|
| Withdrawn | 1 | 13 | RoW | KB407 (Nebulization) | Krystal Biotech, Inc., Novotech (Australia) Pty Limited | Cystic Fibrosis | 07/24 | 10/24 | | |
|
NCT05504837: A Study Assessing KB407 for the Treatment of Cystic Fibrosis |
|
|
| Recruiting | 1 | 12 | US | KB407 (Nebulization) | Krystal Biotech, Inc. | Cystic Fibrosis | 07/24 | 07/24 | | |
|
| Recruiting | 1 | 20 | US | Symdeko, Orkambi, Ivacaftor | University of Alabama at Birmingham | Cystic Fibrosis | 09/24 | 01/25 | | |
ABCI, NCT05802264: Study to Assess Amphotericin B Cystetic for Inhalation () Doses in Healthy Volunteers & People With Cystic Fibrosis |
|
|
| Recruiting | 1 | 84 | RoW | ABCI, Amphotericin B Cystetic for Inhalation, Placebo | Cystetic Medicines, Inc., DevPro Biopharma | Cystic Fibrosis | 12/24 | 12/24 | | |
NCT04624490: Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease |
|
|
| Recruiting | 1 | 260 | US | Hyperpolarized Xe129, HP Xenon | Mario Castro, MD, MPH | Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease | 10/25 | 10/26 | | |
